Corcept Therapeutics shares are trading higher after the company reported better than expected Q2 financial results and raised its FY24 revenue guidance above estimates. Also, HC Wainwright & Co and Piper Sandler raised their respective price targets on the stock.
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics shares are trading higher after the company reported better than expected Q2 financial results and raised its FY24 revenue guidance above estimates. Additionally, HC Wainwright & Co and Piper Sandler raised their respective price targets on the stock.
July 30, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics shares are trading higher due to better than expected Q2 financial results and an increase in FY24 revenue guidance. HC Wainwright & Co and Piper Sandler also raised their price targets on the stock.
The better than expected Q2 financial results and raised FY24 revenue guidance are positive indicators for Corcept Therapeutics. Additionally, the increased price targets from HC Wainwright & Co and Piper Sandler further support a positive short-term outlook for the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100